News

Symrise invests in innovative enzymatic technology with sugar alternative experts Bonumose

Symrise AG has signed a minority investment agreement with Bonumose. The early-stage food ingredient manufacturer specializes in the affordable production of delicious, good-for-you rare monosaccharides (alternatives to sucrose) such as tagatose and allulose. With this strategic transaction, Symrise will accelerate growth in its sugar reduction initiatives. The area represents a high-priority focus for the North America region within the Taste, Nutrition & Health segment.

“This exciting investment forges a strategic partnership. It will enhance our flavor and taste balancing technologies with Bonumose’s innovative and economical tagatose and other alternative sweetening solutions. Combining our technologies, will enable us to offer our customers new pathways to sugar reduction and taste balancing solutions. In turn, this will allow them to reduce sugar while optimizing the taste of better-for-you products for their consumers. This applies especially in the beverage and ice-cream categories. Health forms a growing focus category for Symrise. With the support of Bonumose’s enzymatic expertise, we can bring novel and disrupting ingredients to the marketplace together”, said Nick Russell, Senior Vice President – Business Incubation Group, Symrise AG.

Bonumose opened a new R&D facility and manufacturing plant earlier this year. The facility allows for quality, consistent, and economic production of their growing portfolio of sugar alternatives. Bonumose was founded in 2016 as a start-up. It continues to grow thanks to their patented enzymatic technology. This allows for the sustainable bulk production of healthy ingredients from globally-abundant plant material.

Ed Rogers, Bonumose Chief Executive Officer and Co-Founder, said: “We feel enthusiastic about the future and the growth that the investment and partnership with Symrise enables. Now, we are coupling our expertise in tagatose and other naturally-occurring sugar alternatives with the extensive Symrise flavor proficiency and expansive portfolio across multiple platforms in both human food and animal nutrition. This creates the opportunity to offer unique value to customers. The strength of Symrise as an augmented flavor house paired with Bonumose’s patented enzymatic technology will enable cutting edge solutions to sugar reduction.”

Recent News

04/22/2026

RIVANNA expands multi-site clinical study for Accuro XV musculoskeletal imaging system

RIVANNA®, developer of AI-enabled clinical decision-support solutions, announced that it has expanded its clinical studies evaluating Accuro® XV, the company’s musculoskeletal imaging system, from two to eight sites nationwide. This expansion follows execution of a funding option by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response

04/22/2026

Luminoah Announces FDA Clearance of the Luminoah Flow Enteral Nutrition System, A Brighter Future for Tube Feeding

Luminoah, a medical technology company focused on modernizing enteral nutrition, today announced it has received U.S. Food and Drug Administration clearance for Luminoah Flow™, an enteral feeding system designed to improve the experience of patients who rely on tube feeding. Luminoah Flow combines portability, precision, and connected technology into a streamlined system designed for both

04/21/2026

GO Virginia Region 7 funds LIFT-VA

On Tuesday, March 24, 2026, GO Virginia Region 7 funded something the Commonwealth has not had before: a structured, credentialed pathway that takes students from their first day in a real biotechnology laboratory all the way to a career in one of the fastest-growing industries in America. The program is called Life-Sciences Innovation & Future